probucol has been researched along with Parkinson Disease in 2 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Probucol is a lipid-lowering phenolic compound with anti-inflammatory and antioxidant properties that has been recently reported as protective in neurotoxicity and neurodegeneration models." | 1.39 | Probucol affords neuroprotection in a 6-OHDA mouse model of Parkinson's disease. ( Colle, D; Dos Santos, AA; Farina, M; Figueiredo, CP; Moreira, EL; Peres, KC; Ribeiro, RP; Santos, DB, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ribeiro, RP | 1 |
| Moreira, EL | 1 |
| Santos, DB | 1 |
| Colle, D | 1 |
| Dos Santos, AA | 1 |
| Peres, KC | 1 |
| Figueiredo, CP | 1 |
| Farina, M | 1 |
| Ved, R | 1 |
| Saha, S | 1 |
| Westlund, B | 1 |
| Perier, C | 1 |
| Burnam, L | 1 |
| Sluder, A | 1 |
| Hoener, M | 1 |
| Rodrigues, CM | 1 |
| Alfonso, A | 1 |
| Steer, C | 1 |
| Liu, L | 1 |
| Przedborski, S | 1 |
| Wolozin, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind Multicenter Pilot Study vs. Placebo for the Evaluation of Efficacy and Tolerability of Tauroursodeoxycholic Acid Administered by Oral Route as Add on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis[NCT00877604] | Phase 2 | 34 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Responder patients were defined as those subjects showing an improvement of at least 15% in the ALSFRS-R slope during the treatment period as compared to the lead-in period. (NCT00877604)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| TUDCA | 13 |
| Placebo | 6 |
2 other studies available for probucol and Parkinson Disease
| Article | Year |
|---|---|
Probucol affords neuroprotection in a 6-OHDA mouse model of Parkinson's disease.
Topics: Animals; Catalase; Corpus Striatum; Dopaminergic Neurons; Lipid Peroxidation; Male; Mice; Motor Acti | 2013 |
Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans.
Topics: 3-Hydroxybutyric Acid; alpha-Synuclein; Amino Acid Sequence; Animals; Animals, Genetically Modified; | 2005 |